Vimarsana
Biggest News Aggregation in the World

Page 2 - Scott Struthers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Scott Struthers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Scott Struthers Today - Breaking & Trending Today

Brokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) PT at $54.00 - Vimarsana News

Brokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) PT at $54.00

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month […]

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Significant Growth in Short Interest - Vimarsana News

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Significant Growth in Short Interest

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 5,220,000 shares, a growth of 6.3% from the March 31st total of 4,910,000 shares. Based on an average trading volume of 802,900 shares, the days-to-cover ratio […]

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $2,013,560.67 in Stock - Vimarsana News

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $2,013,560.67 in Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) CEO Richard Scott Struthers sold 40,951 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $49.17, for a total transaction of $2,013,560.67. Following the transaction, the chief executive officer now directly owns 237,835 shares in […]

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript - Vimarsana News

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript February 29, 2024 Crinetics Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2023 Financial Results Conference Call. At this time […]

Source: yahoo.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $44.90 Average PT from Brokerages - Vimarsana News

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $44.90 Average PT from Brokerages

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target […]

Source: wkrb13.com